MVR0 Stock Overview
A pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Nordic region, rest of Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Medivir AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.23 |
| 52 Week High | SEK 0.34 |
| 52 Week Low | SEK 0.19 |
| Beta | -0.16 |
| 1 Month Change | -1.31% |
| 3 Month Change | -1.31% |
| 1 Year Change | 3.29% |
| 3 Year Change | -75.80% |
| 5 Year Change | -80.85% |
| Change since IPO | -99.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| MVR0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 2.3% | 3.1% | 0.5% |
| 1Y | 3.3% | -13.8% | 7.2% |
Return vs Industry: MVR0 exceeded the German Biotechs industry which returned -13.8% over the past year.
Return vs Market: MVR0 underperformed the German Market which returned 7.2% over the past year.
Price Volatility
| MVR0 volatility | |
|---|---|
| MVR0 Average Weekly Movement | 11.7% |
| Biotechs Industry Average Movement | 7.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.7% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: MVR0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: MVR0's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 10 | Jens Lindberg | www.medivir.com |
Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Nordic region, rest of Europe, and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It is also developing Remetinostat for treating MF cutaneous T-cell lymphoma and basal cell carcinoma, as well as squamous cell carcinoma.
Medivir AB (publ) Fundamentals Summary
| MVR0 fundamental statistics | |
|---|---|
| Market cap | €27.59m |
| Earnings (TTM) | -€10.20m |
| Revenue (TTM) | €613.35k |
45.0x
P/S Ratio-2.7x
P/E RatioIs MVR0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MVR0 income statement (TTM) | |
|---|---|
| Revenue | SEK 7.03m |
| Cost of Revenue | SEK 97.07m |
| Gross Profit | -SEK 90.03m |
| Other Expenses | SEK 26.89m |
| Earnings | -SEK 116.92m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 18, 2025
| Earnings per share (EPS) | -1.04 |
| Gross Margin | -1,280.14% |
| Net Profit Margin | -1,662.48% |
| Debt/Equity Ratio | 0% |
How did MVR0 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/29 18:31 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Medivir AB (publ) is covered by 13 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Morten Larsen | ABG Sundal Collier |
| Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |
| Revi Mehrotra | Credit Suisse |